Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS
International Journal of Molecular Sciences · 06.07.2023 · 24 (13) · 11151
DOI: 10.3390/ijms241311151 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2023. Verfasst von Hang-Soo Park und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Extracellular Vesicles, Mesenchymal Stem Cells. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Chicago.
Abstract (Originalsprache)
Polycystic ovary syndrome (PCOS) is known as the most common endocrine disorder in women. Previously, we suggested that human mesenchymal stem cells (MSCs) can reverse the PCOS condition by secreting factors. Here, we evaluated the therapeutic capability of MSC-derived extracellular vesicles (EVs), also known as exosomes, in both in vitro and in vivo PCOS models. Exosomes were used to treat androgen-producing H293R cells and injected in a mouse model through intraovarian and intravenous injection into a letrozole (LTZ)-induced PCOS mouse model. We assessed the effects of the exosomes on androgen-producing cells or the PCOS mouse model by analyzing steroidogenic gene expression (quantitative real-time polymerase chain reaction (qRT–PCR)), body weight change, serum hormone levels, and fertility by pup delivery. Our data show the therapeutic effect of MSC-derived EVs for reversing PCOS conditions, including fertility issues. Interestingly, intravenous injection was more effective for serum glucose regulation, and an intraovarian injection was more effective for ovary restoration. Our study suggests that MSC-derived exosomes can be promising biopharmaceutics for treating PCOS conditions as a novel therapeutic option. Despite the fact that we need more validation in human patients, we may evaluate this novel treatment option for PCOS with the following clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
ORCID-Profile: Hang-Soo Park, Jin Seok, Farzana Liakath Ali, Mohammad Mousaei Ghasroldasht, Ayman Al-Hendy
Förderung
- University of Chicago
Zitieren
APA
Park, H. S., Cetin, E., Siblini, H., Seok, J., Alkelani, H., Alkhrait, S., Liakath Ali, F., Mousaei Ghasroldasht, M., Beckman, A., & Al-Hendy, A. (2023). Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. International Journal of Molecular Sciences, 24(13), 11151. https://doi.org/10.3390/ijms241311151
Vancouver
Park HS, Cetin E, Siblini H, Seok J, Alkelani H, Alkhrait S, et al. Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. International Journal of Molecular Sciences. 2023;24(13):11151. doi:10.3390/ijms241311151
BibTeX
@article{Park2023,
author = {Park, Hang-Soo and Cetin, Esra and Siblini, Hiba and Seok, Jin and Alkelani, Hiba and Alkhrait, Samar and Liakath Ali, Farzana and Mousaei Ghasroldasht, Mohammad and Beckman, Analea and Al-Hendy, Ayman},
title = {Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {13},
pages = {11151},
doi = {10.3390/ijms241311151}
}
EUVIMED